| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88fd9074e7f5629511f3a410b1316b5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba52d72b4ed45463d43212f65b89f138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f15464328560b348d760bee5ceb34fae |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
| filingDate |
2010-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_354f447b3ad37ce777e35dd68fb44700
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96b5392bdc245e1225d486f145b74c31 |
| publicationDate |
2014-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8802623-B2 |
| titleOfInvention |
PAR-1 antagonists for use in the treatment or prevention of influenza virus type A infections |
| abstract |
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10030024-B2 |
| priorityDate |
2009-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |